Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $19.47 (market cap $8.95B), while State Street SPDR S&P Biotech ETF trades at $154.42. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NCLH | XBI | |
|---|---|---|
Market Cap | $8.95B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $26.94 | $164.28 |
52-Week Low | $14.79 | $85.16 |
Enterprise Value | $23.92B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
